65052-63-3 (盐酸头孢他美,Cefetamet)

盐酸头孢他美;头孢米特;盐酸头孢他美酯;7-[(2-氨基-4-噻唑基-2-甲氧基亚氨-乙酰氨基)-3-甲基-8-氧代-5-硫代-L-氮杂二环[4,2,0]辛-2-烯-2-羧酸;头孢他美酸;7-[(2-氨基-4-噻唑基-2-甲氧基亚氨-乙酰氨基)-3-甲基-8-氧代-5-硫代-L-氮杂二环[4.2.0]辛-2-烯-2-羧酸;头孢他美;头孢他美 USP标准品;头孢噻肟杂质A;[6R-[(6Α,7Β(Z)]]-7-[[(2-氨基-4-噻唑基)(甲氧基亚氨基)乙酰基]氨基]-3-甲基-8-氧代-5-硫杂-1-氮杂二环[4.2.0]辛-2-烯-2-羧酸;头孢噻肟钠杂质A;头孢噻肟EP杂质A;

cefetametpivoxil hydrochloride;Cefetamet;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;CEFETAMET PIVOXIL HCL;Cefotaxime Sodium EP Impurity A;Cefetamet acid;Cefetamet hydrochloride;Cefetametum;CEMT;Deacetoxycefotaxime;(6R,7R)-7-[[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrochloride;Cefotaxime impurity A;Cefotaxime EP impurity A;(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime);3-methyl-7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid;D03424;CEFETAMET [USAN];Cefetametum [Latin];Cefetamet (USAN/INN);CHEBI:135629;CEFOTAXIME IMPURITY A [EP IMPURITY];LY-97964;Ro 15-8074;UNII-4R5TV783X3;MFCD00870989;DTXSID00867110;Cefetamet acid;Cefetamet;Deacetoxycefotaxime;Cefetamet [USAN:INN];LY097964;CEFOTAXIME SODIUM IMPURITY A [EP IMPURITY];65052-63-3;HY-A0111;4R5TV783X3;CEFETAMET [INN];(6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, AldrichCPR;CEFETAMET [USP-RS];(6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;AS-33463;CEFETAMET [WHO-DD];CEFETAMET [USP IMPURITY];MFCD00864836;SCHEMBL65620;FR 13300;AKOS015898798;(6R,7R)-7-(((2Z)-2-(2-AMINOTHIAZOL-4-YL)-2-(METHOXYIMINO)ACETYL)AMINO)-3-METHYL-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID;CEFETAMET [MART.];(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;Ro-15-8074;Deacetoxycefotaxime, 97%;CHEMBL2103764;CS-0014040;DB13504;CEFETAMET [MI];LY-097964;Cepime O;DA-51747;BRD-K27798832-001-01-5;

MFCD00864836

MQLRYUCJDNBWMV-GHXIOONMSA-N

1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1

S1CC(C)=C(C(=O)O)N2C([C@H]([C@@H]12)NC(/C(/C1=CSC(N)=N1)=N\OC)=O)=O

合成盐酸头孢他美酯的中间体。第三代头孢菌素。对革兰阳性菌和阴性菌抗谱广。用于敏感菌所引起的肺炎、咽喉炎、扁桃炎、支气管扩张症、急性支气管炎等。

将2-(2-氨基-4-噻唑基)-2-(甲氧基亚氨基)乙酸悬浮于四氢呋喃中，在0℃下滴加半量的三氯氧磷，保持温度不超过5℃，滴完反应30min。加入二甲基甲酰胺和另一半量的三氯氧磷，在0℃下反应1h，得活性酯(I)的溶液，冷至-5℃备用。7-ADCA、双-三甲基硅脲和乙酸乙酯，在75～77℃下回流2h，得7-ADCA硅酯(Ⅱ)的溶液，冷至-5℃。将其和活性酯(工)的溶液合并，在-5～0℃下搅拌2h。升至15"C，加水，搅拌30min。分出水层，用****溶液调至Ph=2.6～3.0，放置析出结晶。过滤，丙酮重结晶，得头孢他美，收率82%。